Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Edwards Lifesciences (NY:EW)

74.72 +2.07 (+2.85%)
Streaming Delayed Price Updated: 3:45 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edwards Lifesciences

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Peering Into Edwards Lifesciences's Recent Short Interest
Edwards Lifesciences's (NYSE:EW) short percent of float has risen 6.33% since its last report. The company recently reported that it has 5.15 million shares sold short, which is 0... 
Via Benzinga
Here's How Much $1000 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth Today
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 15 years by 16.51% on an annualized basis producing an average annual return of 22.72%. Currently, Edwards Lifesciences has a... 
Via Benzinga
Where Edwards Lifesciences Stands With Analysts
Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter: 
Via Benzinga
7 Growth Stocks That Analysts Love Right Now
These growth stocks are receiving buy ratings and significantly higher price targets from analysts, making them ideal names to consider. 
Via InvestorPlace
Why Jim Cramer Prefers These 2 Semiconductor Stocks
On CNBC’s "Mad Money Lightning Round," Jim Cramer said SoFi Technologies, Inc. (NASDAQ: SOFI) has been getting destroyed. 
Via Benzinga
Edwards Lifesciences Clocks 10% Top-Line Growth In Q1; Forecasts Lower Than Expected Q2 Sales
 
Via Benzinga
Medtech Giant Edwards Lifesciences Tumbles Despite First-Quarter Beat
The medtech giant narrowly beat first-quarter sales and earnings views. 
Via Investor's Business Daily
Earnings Scheduled For April 26, 2022
Companies Reporting Before The Bell • First American Financial (NYSE:FAF) is estimated to report quarterly loss at $0.09 per share on revenue of $46.41 million. 
Via Benzinga
Expert Ratings for Edwards Lifesciences
Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter: 
Via Benzinga
Stock Market Volatile; Apple, Facebook, Amazon Are Key Earnings, Tesla CEO Elon Musk Buys Twitter: Weekly Review
The Nasdaq hit its lowest level since 2020. Apple and Facebook led key earnings. 
Via Investor's Business Daily
If You Invested $100 In Edwards Lifesciences 20 Years Ago, Here's How Much You Would Have Today
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 14.71% on an annualized basis producing an average annual return of 21.87%. Currently, Edwards Lifesciences has a... 
Via Benzinga
Recap: Edwards Lifesciences Q1 Earnings
Edwards Lifesciences (NYSE:EW) reported its Q1 earnings results on Tuesday, April 26, 2022 at 04:15 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Market Briefing For Monday, April 25
It's clearly on the edge of the generals completing their retreat to join troops already in the trenches. Nevertheless the same variables prevail; it's hard to project any sustainable rallies. 
Via Talk Markets
Where Edwards Lifesciences Stands With Analysts
Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter: 
Via Benzinga
Establishment Labs Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
Establishment Labs stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 92, up from 87 the day before. 
Via Investor's Business Daily
Inspire Medical Systems Stock Scores Relative Strength Rating Upgrade
Inspire Medical System stock reached an key technical benchmark, seeing its Relative Strength (RS) Rating jumping to 91. 
Via Investor's Business Daily
Five Of The Best Chinese Stocks To Keep An Eye On
This year has been a stellar one for the Chinese stock market. After a year that saw the Shanghai Stock 
Via Best Stocks
Pfizer Stock, Raytheon Lead 5 Stocks Near Buy Points
Pfizer, Raytheon lead stocks shielded from geopolitics and rate hikes. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022
Upgrades 
Via Benzinga
Raytheon, Shell Lead Five Stocks Setting Up, Breaking Out From Strong Sectors
Raytheon and Shell are just below buy points. They have good company. 
Via Investor's Business Daily
7 Medical Device Stocks to Buy as Covid-19 Fears Fade
With concerns about Covid-19 fading into the rearview mirror, the normalization of healthcare could benefit these medical device stocks. 
Via InvestorPlace
3 Top S&P 500 Stock Market Gainers Today: Medicals Lead As This Sector Reverses Hard
Medical and gold stocks led the S&P 500. Transport stocks were big losers. 
Via Investor's Business Daily
FDA Approves Edwards Lifesciences' Resilia Valve For Mitral Replacement Surgery
The FDA has approved Edwards Lifesciences Corp's (NYSE: EW) Mitris Resilia valve, a tissue valve replacement specifically designed for the heart's mitral... 
Via Benzinga
What 9 Analyst Ratings Have To Say About Edwards Lifesciences
Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
Analyst Ratings For Edwards Lifesciences
Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022
Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to... 
Via Benzinga
This Foreboding Sign Looms Over Edwards Lifesciences's Chart
If history is any guide, there may be trouble ahead for shares of Edwards Lifesciences (NYSE:EW). A so-called "death cross" has formed on its chart and, not surprisingly, this... 
Via Benzinga
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09... 
Via Benzinga
Stock Market Whipsaws Lower On Hawkish Fed, Tesla; Apple, Microsoft Earnings Strong: Weekly Review
Microsoft and Apple earnings were strong, but the correction is getting worse. 
Via Investor's Business Daily
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.